A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations

Cancer Research and Treatment · Published 2026-05-04 · DOI 10.4143/crt.2025.1352

Authors being retrieved — see the publisher record. https://doi.org/10.4143/crt.2025.1352

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Tumor-Intrinsic Hepatocyte Arm-Level Genomic States Shape Immunotherapy Response Heterogeneity in Hepatocellular Carcinoma · Cancer Research and Treatment · 2026 · Same journal
Therapeutic Potential of Engineered Stem Cell Line with Chemokine Receptors and TRAIL/CD::UPRT in Glioblastoma Treatment · Cancer Research and Treatment · 2026 · Same journal
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023 · Cancer Research and Treatment · 2026 · Same journal
A Prospective Study of Non‑Treating Medical Institution Use for Supportive Care During Adjuvant Chemotherapy After Curative Surgery (PRO-SUCCESS) · Cancer Research and Treatment · 2026 · Same journal
A Phase I/II Trial to Evaluate the Safety and Efficacy of Continuous Positive Airway Pressure in Volumetric Modulated Arc Therapy for Breast Cancer · Cancer Research and Treatment · 2026 · Same journal
Individual SGLT-2 Inhibitors and Risk of New-Onset Cancer in Type 2 Diabetes: A Nationwide Population-Based Cohort Study · Cancer Research and Treatment · 2026 · Same journal
Integrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER Program · Cancer Research and Treatment · 2026 · Same journal
Biomarker Testing Practices for Non-small Cell Lung Cancer: Survey Insights from South Korean Pathology Laboratories · Cancer Research and Treatment · 2026 · Same journal
Perceptions and Use of Complementary and Alternative Medicine among Patients with Cancer and Their Family Members (KCSG PC21-19) · Cancer Research and Treatment · 2026 · Same journal
Distinct Evolutionary Dynamics of HER2-Ultralow Versus HER2-Null from Residual to Metastatic Disease in Non-pCR Breast Cancer · Cancer Research and Treatment · 2026 · Same journal